Media coverage about Synlogic (NASDAQ:SYBX) has trended somewhat negative this week, Accern Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synlogic earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.9633707965154 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

A number of analysts have weighed in on SYBX shares. Zacks Investment Research lowered shares of Synlogic from a “hold” rating to a “sell” rating in a research note on Wednesday, November 22nd. Wedbush began coverage on shares of Synlogic in a research note on Monday, November 27th. They issued an “outperform” rating and a $20.00 price target for the company. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $19.67.

Shares of Synlogic (NASDAQ SYBX) traded down $0.15 on Thursday, reaching $10.59. 4,600 shares of the company traded hands, compared to its average volume of 38,400. Synlogic has a 12 month low of $8.76 and a 12 month high of $23.00. The company has a market capitalization of $174.90, a PE ratio of -1.12 and a beta of 3.17.

Synlogic (NASDAQ:SYBX) last posted its quarterly earnings data on Monday, November 13th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($1.16). sell-side analysts expect that Synlogic will post -5.42 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Synlogic (SYBX) Getting Somewhat Critical Press Coverage, Analysis Shows” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at

Synlogic Company Profile

Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).

Insider Buying and Selling by Quarter for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.